- Proximity to Discovery (PtD) Secondment Awards - OPEN (responsive mode)
Applications can be submitted any time for consideration.
UCL TRO invites members of the UCL community to apply for funding under the Proximity-to-Discovery award which was granted to the TRO from the MRC. The secondment awards are suitable for UCL researchers looking to promote their engagement in knowledge transfer to companies, social enterprises, charities and other non-academic organisations.
Further information about the scheme and how to apply can be found below:
- The review panel consists of the SLMS Vice Deans of Enterprise
- List of funded projects - PtD Secondment Awards
- Therapeutic Acceleration Support (TAS) Fund - Round 3 OPEN - closes 5pm, 27 April 2018.
Click here for guidance on how to apply.
The UCL Therapeutic Acceleration Support (TAS) Fund aims to accelerate the transition from discovery science to the early stages of therapeutic development, by providing responsive and flexible funding to overcome specific “hurdle(s)” in translational progression, allowing projects to position themselves to apply for MRC Developmental Pathway Funding Scheme (DPFS) or similar follow-on funding schemes. This award includes a ring-fenced fund of £75,000 to support projects that address the aims of the Global Challenges Research Fund.
Managed by the Translation Research Office, the TAS fund (total of £1.2M) is supported by the MRC Confidence in Concept scheme, Wellcome Trust Institutional Strategic Support Fund and the three NIHR Biomedical Research Centres (BRC) affiliated with UCL (University College London Hospitals NHS Foundation Trust (UCLH) BRC, Great Ormond Street Hospital (GOSH) BRC and Moorfields BRC).
The review panel is populated by internal and external academics, clinicians and professionals who have experience of translation and commercialisation. List of Panel Members.
TAS fund Round 3: Opens 19th March 2018 - Closes 5pm, 27 April 2018
Prior to preparing an application please contact the Translational Research Office to check that your project is within remit for the scheme: The main point of contact is Dr Simon Eaglestone.
TAS fund Round 2:
The TAS Fund Panel met on the 5th December 2017 to consider 22 project applications. The proposals encompassed modalities aligned across all of the Therapeutic Innovation Networks (TINs): 10 applications within the Small Molecule TIN, 9 within Device & Diagnostics, 2 within the Cell, Gene & Regenerative Medicine TIN and 1 within the Biologics TIN.
7 individual project proposals were each awarded TAS funding up to £75k (directly incurred costs only) for up to 12 months.
TAS fund Round 1:
The TAS Fund Panel met on the 3rd July 2017 to consider the 21 project applications. The proposals encompassed modalities aligned across all of the Therapeutic Innovation Networks (TINs): 6 applications within the Cell, Gene & Regenerative Medicine TIN; 2 applications Devices; 1 application Diagnostics & 12 applications Small Molecule TIN.
10 individual project proposals were each awarded TAS funding up to £75k (directly incurred costs only) for up to 12 months.
Each of the awarded projects have been allocated a TRO Translational Research Manager to work alongside the team providing guidance and support to achieve their TAS-funded translational progression. Moreover, all applicants to the scheme will be provided feedback and encouraged to develop their proposal, building upon the comments and advice received from the Panel and reviewers.